


STATIN

NEWSLETTER



A CURATED WEEKLY OVERVIEW OF ALL STATIN PUBLICATIONS

Update week 51 & 52 - 2021

Dr. Peter Lansberg is a Dutch lipidologist, educator and innovator. He has been instrumental in setting up The Dutch National Lipid Clinic Network, the Dutch Lipid Clinic Criteria for Familial Hypercholesterolemia (FH), and the Dutch National FH screening program

The Statin Newsletter will keep you up-to-date with all recent statin publications. Based on a curated approach to select relevant articles.

For live updates you can follow me on twitter

Key Publications

1. **Rhabdomyolysis risk; statins + sacubitril/valsartan**
2. **Metabolic effects of statins + ezetimibe in diabetics,**
3. **VTE risk reduced by rosuvastatin in VTE**
4. **Statins in primary prevention - Real world data**
5. **No ICH harm in post ischemic stroke patients with LDL-c <70 mg/dL**

High intensity statin + sacubitril/valsartan and rhabdomyolysis risk

Several reports on drug interactions leading to rhabdomyolysis with the use of sacubitril/valsartan and high potency statins were recently published. Reports submitted to the United States Food and Drug Administration's Adverse Event Reporting System (FAERS) from

1991 to Q4/2020 were used to query if exposure of statins alone, sacubitril/valsartan alone, and statin combined with sacubitril/valsartan. Proportional reporting ratios (PRR) were queried in the FAERS, and a lower limit of 95% CI ≥ 2.0 was interpreted as a safety signal. No safety signal was detected for statins combined with sacubitril/valsartan, except for rosuvastatin and sacubitril/valsartan. The PRRs for rhabdomyolysis were 2.39 (2.01 to 2.84) with rosuvastatin alone and 2.06 (2.01 to 2.12) for sacubitril/valsartan alone. For atorvastatin + sacubitril/valsartan, the PRR was 0.95 (0.64 to 1.40). Combined statin and sacubitril/valsartan seem safe; however, further evidence is warranted to explore mechanisms for additive or synergistic effects on rhabdomyolysis.

Sunaga T, Ryo Y. Potential Safety Signals for Rhabdomyolysis Associated With High-Potency Statin Use With or Without Sacubitril/Valsartan. *Am J Cardiol* 2021.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=34963512>

Meta-analysis statins + ezetimibe in diabetics

Statins share a pro-diabetogenic effect that is dose and intensity dependent. This meta-analysis explored the adverse metabolic properties of ezetimibe alone or when combined with statins in patients with type 2 diabetes. For this meta-analysis, 17 articles were included, and both lipid and glucose parameters were explored in patients who used statin monotherapy or a combination of ezetimibe and statins. All lipid parameters improved significantly with the combination therapy compared to statin monotherapy. The difference in means is 0.691(0.534–0.847). Superior levels of HDL-C, total cholesterol, triglyceride, and apolipoprotein B, but not apolipoprotein A1, were noted with combination therapy compared to statin monotherapy. Fasting blood glucose levels were significantly lower with ezetimibe compared to statin monotherapy. No safety signals were observed when ezetimibe + statins were compared to statins. Monotherapy. The authors concluded that combining statins with ezetimibe improves the overall lipid spectrum and glycaemic biomarkers without increasing the risk for adverse events.

Shin KH, Choi HD. **Comparison of Efficacy and Safety of Statin-Ezetimibe Combination Therapy with Statin Monotherapy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Studies.** *Am J Cardiovasc Drugs* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34927215>

Rosuvastatin reduces VTE risk by lowering PPL activity

Prevention of venous thromboembolism (VTE) remains a therapeutic challenge. Currently used oral anticoagulants are effective, but their use is associated with an increased bleeding risk. Subgroup analysis of several statin trials have suggested that statins can reduce the risk of incident and recurrent VTE's; however, little is known regarding the mechanism responsible for this anticoagulant effect. In this RCT (N=255), patients with a history of VTE stopped using oral anticoagulants and were randomized to rosuvastatin 20 mg (N=131) or placebo (N=124). Blood samples were collected at the start of the study and after 28 days. The endpoints of this trial were procoagulant phospholipids (PPL), using a factor Xa dependent clotting assay, and plasma concentration of extracellular vesicles (EV). Rosuvastatin treatment was associated with a 22% (-38.2 to -5.8) reduction in PPL activity. In patients with a history of PE, PPL activity was reduced by 37% (-62.9 to -11.2). These observed PPL activity changes were independent of total cholesterol decrease or change in levels of total-or platelet-derived EVs. The authors concluded that rosuvastatin use was associated with a substantial decrease in PPL activity; this mechanism is a plausible explanation for the reduction in VTE risk observed in patients using statins.

Ramberg C, Hindberg K, Biedermann JS *et al.* **Rosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: A randomized controlled trial.** *Journal of thrombosis and haemostasis* : JTH 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34953155>

Statin in primary prevention following guidelines or RCT's?

For this analysis, the authors creatively combined data collected in the Copenhagen General Population Study (CGPS) and data from randomized controlled statin trials to estimate the accuracy of commonly used guideline-based recommendations for primary prevention statin use. The following guidelines were evaluated: American College of Cardiology/American Heart Association (ACC/AHA), Canadian Cardiovascular Society(CCS), UK National Institute for Health and Care Excellence (NICE), and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS). In total, 79 171 participants of the CGPS were free of ASCVD and not using statins at baseline. After a follow-up period of 8.2 years, 4031 events accrued in this cohort. Of the individuals eligible for statin therapy with the ACC/AHA, CCS, NICE, and ESC/EAS guidelines, 86%, 88%, 88%, and 84% had direct RCT evidence of statin efficacy, respectively (guideline-positive & RCT-positive). This group represented 26–37% of all CGPS individuals. Guideline-positive & RCT-negative individuals represented 5–7%, guideline-negative & RCT positive individuals 28–39%, and guideline-negative & RCT-negative individuals represented 30–31%. The ASCVD events per 1000 person-years were 11.4–12.7 (guideline-positive & RCT-positive), 6.3–8.0 (guideline positive & RCT-negative), 4.2–5.2 (guideline-negative & RCT-positive), and 2.3–2.5 (guideline-negative & RCT negative), respectively, while the corresponding NNT to prevent one event in

10 years using high-intensity statin were 19–21, 30–32, 48–60, and 105–125, respectively. The authors concluded that the evaluated data strongly supports the guideline-recommended use of risk calculators as a starting point for a patient-physician discussion on the initiation of statin for primary prevention. More accurate identification of patients is more likely to benefit from evidence-based statin treatment. Of note, patients not qualifying for guideline-based statin treatment but eligible because of RCT evidence may also benefit from initiating statins.

Mortensen MB, Nordestgaard BG. Guidelines versus trial-evidence for statin use in primary prevention: The Copenhagen General Population Study. *Atherosclerosis* 2022; 341:20-26. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959205>

Is a low LDL-c (<70 mg/dL) associated with an increased ICH risk?

The Treat Stroke to Target (TST) study included patients with an ischemic stroke or evidence of atherosclerosis. Patients were randomized to achieve an LDL-c <70 mg/dL (N=1440) or 100±10 mg/dL (N=1433). In this sub-analysis, the risk for an intracranial hemorrhage (ICH) in the two treatment arms was re-evaluated. Over a median follow-up of 3 years, 31 ICH occurred, 18 in patients that achieved and LDL<70 mg/dL and 13 in the higher target group; 3.21/1000 patient-years (2.38–4.04) and 2.32/1000 patient-years (1.61–3.03], respectively. ICH risk factors at baseline failed to predict events, however uncontrolled hypertension; HR 2.51 (1.01–6.31, P=0.041), orals anticoagulants; HR 2.36 (1.00–5.62, P=0.047) during the trial were significant predictors. A low on-treatment LDL-c was not associated with ICH, Amarenco P, Kim JS, Labreuche J *et al.* Intracranial Hemorrhage in the TST Trial. *Stroke* 2022; 53:457-462. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34963300>

Relevant Publications

1. Zhang L, Olalere D, Mayrhofer T *et al.* Differences in Cardiovascular Risk, Coronary Artery Disease, and Cardiac Events Between Black and White Individuals Enrolled in the PROMISE Trial. *JAMA cardiology* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34935857>
2. Xi N, Wang Y, Zhou J *et al.* [Influence of ApoE gene polymorphisms on therapeutic effects of lipid-lowering statins among patients with ischemic cerebral infarction]. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi* 2022; 39:94-98. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964977>
3. Wu Y, Li F, Wang Y *et al.* Standard-Dose Atorvastatin Treatment in Patients With Symptomatic Middle Cerebral Artery Atherosclerotic Stenosis: A Vessel Wall Magnetic Resonance Imaging Study. *Frontiers in neurology* 2021; 12:693397. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956036>
4. Wesołowska A, Winiarska H, Owoc J *et al.* Effects of Low-Dose Atorvastatin on the Peripheral Blood Mononuclear Cell Secretion of Angiogenic Factors in Type 2 Diabetes. *Biomolecules* 2021; 11. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34944529>
5. Warden BA, Cardiology BA, Purnell JQ *et al.* Real-world utilization of bempedoic acid in an academic preventive cardiology practice. *J Clin Lipidol* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34924351>
6. van der Laarse A, Cobbaert CM. Biochemical risk factors of atherosclerotic cardiovascular disease: from a narrow and controversial approach to an integral approach and precision medicine. *Expert Rev Cardiovasc Ther* 2021; 19:1085-1096. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34937476>
7. Thongnak L, Pengrattanachot N, Promsan S *et al.* The combination of dapagliflozin and statins ameliorates renal injury through attenuating the activation of inflammasome-mediated autophagy in insulin-resistant rats. *Journal of biochemical*

- [and molecular toxicology_2021:e22978. http://www.ncbi.nlm.nih.gov/pubmed/?term=34939712](http://www.ncbi.nlm.nih.gov/pubmed/?term=34939712)
8. Taha H, Kandil H, Farag N *et al.* Egyptian practical guidance in hypertriglyceridemia management 2021. The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology_2021; 73:107. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34928475>
 9. Saul H, Gursul D, Cassidy S *et al.* Statins do not commonly cause muscle pain and stiffness. Bmj_2021; 375:n3060. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34965931>
 10. Radbakhsh S, Kovanen PT, Sahebkar A. Regulating NETosis: An emerging facet of statin pleiotropy. Drug discovery today_2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958959>
 11. Kidambi BR, Purohit V, Bajpai S *et al.* Is the use of high-intensity atorvastatin associated with memory impairment? Indian Heart J_2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34933015>
 12. Hashimoto T, Minami Y, Asakura K *et al.* Lower levels of low-density lipoprotein cholesterol are associated with a lower prevalence of thin-cap fibroatheroma in statin-treated patients with coronary artery disease. J Clin Lipidol_2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34924352>
 13. Gobbel GT, Matheny ME, Reeves RR *et al.* Leveraging structured and unstructured electronic health record data to detect reasons for suboptimal statin therapy use in patients with atherosclerotic cardiovascular disease. Am J Prev Cardiol_2022; 9:100300. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950914>
 14. Gnanenthiran SR, Agarwal A, Patel A. Frontiers of cardiovascular polypills: From atherosclerosis and beyond. Trends Cardiovasc Med_2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34973412>
 15. Glober N, Stewart L, Seo J *et al.* Incidence and characteristics of arterial thromboemboli in patients with COVID-19. Thromb J_2021; 19:104. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34930306>
 16. Gaitán-Duarte HG, Álvarez-Moreno C, Rincón-Rodríguez CJ *et al.* Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial. EClinicalMedicine_2022; 43:101242. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34957385>
 17. Furtado JD, Ruotolo G, Nicholls SJ *et al.* Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease. Arterioscler Thromb Vasc Biol_2022; 42:227-237. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34937388>
 18. Beltrán Romero LM, Vallejo-Vaz AJ, Muñoz Grijalvo O. Cerebrovascular Disease and Statins. Frontiers in cardiovascular medicine_2021; 8:778740. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34926626>
 19. Adams A, Bojara W, Romanens M. Effect of Statin Treatment in Patients With Advanced Carotid Atherosclerosis: An Observational Outcome Study. Cardiology research_2021; 12:335-339. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970362>
 20. Wu L, Cheng Y, Peng S *et al.* Sphingosine Kinase 1 Plays an Important Role in Atorvastatin-Mediated Anti-Inflammatory Effect against Acute Lung Injury. Mediators Inflamm_2021; 2021:9247285. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970075>
 21. Wang Y, Zhou C, Yu T, Zhao F. Correlation between Changes in Serum RBP4, hs-CRP, and IL-27 Levels and Rosuvastatin in the Treatment of Coronary Heart Disease. J Healthc Eng_2021; 2021:8476592. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34956579>
 22. Seo SI, Park CH, Kim TJ *et al.* Aspirin, metformin, and statin use on the risk of gastric cancer: A nationwide population-based cohort study in Korea with systematic review and meta-analysis. Cancer medicine_2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34970858>
 23. Saito J, Kaneko K, Abe S *et al.* Pravastatin concentrations in maternal serum, umbilical cord serum, breast milk and neonatal serum during pregnancy and

- lactation: A case study. Journal of clinical pharmacy and therapeutics 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34951046>
24. Righetti L, Dall'Asta C, Bruni R. Risk Assessment of RYR Food Supplements: Perception vs. Reality. Front Nutr 2021; 8:792529. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950692>
 25. Pose E, Solà E, Lozano JJ *et al.* Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis. Hepato Commun 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964311>
 26. Lewis MM, Albertson RM, Du G *et al.* Parkinson's Disease Progression and Statins: Hydrophobicity Matters. Journal of Parkinson's disease 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34958045>
 27. Lee WM, Bae JH, Chang Y *et al.* Effect of Nutrition Education in NAFLD Patients Undergoing Simultaneous Hyperlipidemia Pharmacotherapy: A Randomized Controlled Trial. Nutrients 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34960005>
 28. Kwon MJ, Kang HS, Kim JH *et al.* Association between Statin Use and Gastric Cancer: A Nested Case-Control Study Using a National Health Screening Cohort in Korea. Pharmaceuticals (Basel, Switzerland) 2021; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959682>
 29. Kurani SS, Lampman MA, Funni SA *et al.* Association Between Area-Level Socioeconomic Deprivation and Diabetes Care Quality in US Primary Care Practices. JAMA network open 2021; 4:e2138438. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964856>
 30. Heidari B, Babaei M, Yosefghahri B. Prevention of Osteoarthritis Progression by Statins, Targeting Metabolic and Inflammatory Aspects: A Review. Mediterr J Rheumatol 2021; 32:227-236. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964026>
 31. Grabarek BO, Boroń D, Morawiec E *et al.* Crosstalk between Statins and Cancer Prevention and Therapy: An Update. Pharmaceuticals (Basel, Switzerland) 2021; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959621>
 32. Evans MD, McDowell SA. Pleiotropic Effects of Statins: New Therapeutic Approaches to Chronic, Recurrent Infection by *Staphylococcus aureus*. Pharmaceutics 2021; 13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34959329>
 33. Ellimuttill TM, Harrison K, Rollins AT *et al.* Effect of Statin Intensity on the Progression of Cardiac Allograft Vasculopathy. Card Fail Rev 2021; 7:e15. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950505>
 34. Eggers KM, Jernberg T, Lindahl B. Risk-associated management disparities in acute myocardial infarction. Scientific reports 2021; 11:24488. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34966178>
 35. Chen J, Huang C, Zhang T *et al.* The effects of statins on hyperandrogenism in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reproductive biology and endocrinology : RB&E 2021; 19:189. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34930305>
 36. Chang R, Liu SY, Zhao LM. Impact of demographic characteristics and antihyperglycemic and cardiovascular drugs on the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes mellitus: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021; 100:e27802. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34964748>
 37. Chang JC, Chen YJ, Chen IC *et al.* Perinatal Outcomes After Statin Exposure During Pregnancy. JAMA network open 2021; 4:e2141321. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34967881>
 38. Caldara R, Maffi P, Costa S *et al.* COVID-19 in Solid Organ Transplant Recipient: Exploring Cumulative Incidence, Seroprevalence and Risk Factors for Disease Severity. Biology (Basel) 2021; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34943264>
 39. Bermudez-Lopez M, Perpiñan H, Amigo N *et al.* Advanced lipoprotein parameters could better explain atheromatosis in non-diabetic chronic kidney disease patients. Clinical kidney journal 2021; 14:2591-2599. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34950470>

40. Avan R, Sahebnaasagh A, Hashemi J *et al.* Update on Statin Treatment in Patients with Neuropsychiatric Disorders. Life (Basel) 2021; 11.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34947895>
41. Antonenko A, Leahy A, Babenko M, Lyons D. Low dose hydrophilic statins are the preferred agents for females at risk of osteoporosis. Bone Rep 2022; 16:101152.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34934779>

Basic Science

1. Yu Y, Zhang YH, Liu L *et al.* Bioinformatics analysis of candidate genes and potential therapeutic drugs targeting adipose tissue in obesity. Adipocyte 2022; 11:1-10.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34964707>
2. Pohlen M, Aguiar Zdovc J, Trontelj J *et al.* Relative bioavailability enhancement of simvastatin via dry emulsion systems: comparison of spray drying and fluid bed layering technology. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34942336>
3. Lee JS, Park SC, Kim SD. Effects of hypercholesterolemia on expansion of abdominal aortic aneurysm in rat model. Journal of cardiothoracic surgery 2021; 16:352.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34961565>
4. Jiang T, Xu L, Zhao M *et al.* Dual targeted delivery of statins and nucleic acids by chitosan-based nanoparticles for enhanced antiatherosclerotic efficacy. Biomaterials 2022; 280:121324. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34933253>
5. Jakab J, Zjalic M, Mikšić Š *et al.* Effect of Metformin and Simvastatin in Inhibiting Proadipogenic Transcription Factors. Curr Issues Mol Biol 2021; 43:2082-2097.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34940118>
6. Gouni S, Strati P, Toruner G *et al.* Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma. Leukemia & lymphoma 2021:1-12.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34969327>
7. Goldberg H, Mohsin FK, Chandrasekar T *et al.* The association of statin subgroups with lower urinary tract symptoms following a prostate biopsy. Can Urol Assoc J 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34941486>
8. Elakkad YE, Mohamed SNS, Abuelezz NZ. Potentiating the Cytotoxic Activity of a Novel Simvastatin-Loaded Cubosome against Breast Cancer Cells: Insights on Dual Cell Death via Ferroptosis and Apoptosis. Breast cancer (Dove Medical Press) 2021; 13:675-689. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34934357>
9. Cai Y, Zhao F. Fluvastatin suppresses the proliferation, invasion, and migration and promotes the apoptosis of endometrial cancer cells by upregulating Sirtuin 6 (SIRT6). Bioengineered 2021; 12:12509-12520. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34927546>
10. Al-Hashimi NN, Shtaiwi MH, Hamed SH *et al.* Development of Dioctyl Phthalate@Fe(3)O(4) Nanocomposite Reinforced Hollow Fiber Solid/ Liquid Phase Microextraction Followed by HPLC-DAD for the Determination of Atorvastatin and Gemfibrozil in Human Urine. Pharm Nanotechnol 2021; 9:372-382.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34951377>

To subscribe to the Statin Literature Update Service Click [HERE](#)



Facebook



Twitter



Website

mailing address:
lansberg@gmail.com

© P.J. Lansberg